1 Day
المصدر:
The Fiscal Times
المصدر: The Fiscal Times
1 DayThe Fiscal Times
المصدر: The Fiscal Times
1 Dayجاهز للتشغيل
جاهز للتشغيل
Moderna's shares more than doubled after announcing positive initial results from a study of an experimental mRNA-based cancer vaccine, intismeran, developed with Merck. The vaccine, tailored to individual tumor mutations and paired with Merck’s Keytruda, showed patients experienced longer periods without cancer recurrence compared to those receiving only Keytruda in melanoma cases. The companies plan to present full results at an upcoming international medical conference.
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading